Can Drug Repurposing Accelerate Precision Oncology?

Area of Science:

• Oncology
• Pharmacology
• Genomics

Background:

• Advancements in cancer diagnostics and genomic profiling necessitate novel, personalized cancer treatments.
• Developing new anticancer drugs is a complex, expensive, and lengthy process.
• Drug repurposing presents an attractive strategy to accelerate the development of new cancer therapies.

Purpose of the Study:

• To review strategies for repurposing anticancer agents.
• To discuss the translation of preclinical findings into clinical trial designs.
• To highlight challenges and opportunities in drug repurposing for precision oncology.

Main Methods:

• Literature review of drug repurposing strategies in oncology.
• Analysis of preclinical to clinical translation pathways.
• Examination of challenges and future directions in precision oncology drug development.

Main Results:

• Drug repurposing can significantly shorten timelines and reduce costs compared to de novo drug development.
• Successful repurposing requires careful consideration of preclinical data, trial design, and regulatory pathways.
• Combinatorial approaches show promise for enhancing the efficacy of repurposed drugs in precision oncology.

Conclusions:

• Drug repurposing is a viable and efficient approach to accelerate the availability of novel cancer treatments.
• Overcoming challenges in drug repurposing is crucial for maximizing its potential in precision oncology.
• Strategic implementation of drug repurposing, particularly with combination therapies, can advance personalized cancer care.